ArticleGastroenterology & hepatology2018
Care of Patients Following Cure of Hepatitis C Virus Infection.
Article in Gastroenterology & hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Article
- Long-term psychological and functional outcomes after hepatitis C eradication with direct-acting antivirals: an 80-month follow-up study.Frontiers in psychiatry · 2026Article
- Trends in Hospitalizations of Patients with Hepatitis C Virus in Poland between 2012 and 2022.Journal of clinical medicine · 2024Article
- Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis.Seminars in cell & developmental biology · 2020Review
- Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure.Current treatment options in infectious diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vast majority of persons with chronic hepatitis C virus (HCV) infection will achieve virologic cure with the current direct-acting antiviral therapies. Prevention of reinfection is an important aspect of postcure management and key to the elimination of HCV infection globally. Equally important aspects of postcure care are the prevention of liver disease progression and the management of complications in patients who have significant fibrosis at the time of achieving cure. Patients with advanced fibrosis need to remain under surveillance for liver complications, including hepatocellular carcinoma. All patients are potentially at risk for liver disease progression if other factors causing liver injury are present, such as harmful levels of alcohol use or risk factors for fatty liver including obesity, diabetes, and other metabolic comorbidities. Fatty liver is a particular threat to the long-term well-being of patients after HCV cure due to the high prevalence of its risk factors in this population. Strong counseling messages and ongoing monitoring are key.
Indexed as
Identifiers
30538603PMC6284341W2988515181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.